// App-Quantinova.ai

274 : A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.

Researchers

Presenter

  • Akash Patnaik

Principal Investigators

  • Justin Kung

  • Philip W. Kantoff

  • Steven P. Balk

  • Glenn J. Bubley

  • Massimo Loda

  • Mary-Ellen Taplin

  • Rosina Lis

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Department of Pathology, Brigham and Womens Hospital, Boston, MADana-Farber Cancer Institute, Boston, MABeth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Boston, MA

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Phosphatase and tensin homolog

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Phosphorylated-AKT

Drug/Treatment

  • CB-7598

  • BKM-120

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved